Press Room

Hovione has been recognized as a Top Employer in all four of its manufacturing sites, in Lisbon (Portugal), Cork (Ireland), East Windsor (NJ) and Macau. Hovione is the first company to be certified as a Top Employer in Macau. Hovione’s 3 other sites, who had achieved Top Employer status in 2023, showed improved results this year.   Lisbon, January 18, 2024, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, is delighted to announce that it has been recognized as a Top Employer in all four of its manufacturing sites. Hovione is the first ever company to be certified as a Top Employer in Macau. This marks a significant milestone in the company's commitment to fostering a supportive workplace environment and providing meaningful and rewarding roles for its team members. It also demonstrates that “One Hovione”, a company´s strategic initiative to give team members an equally high-quality experience across all locations, is delivering.  The certification program by the Top Employers Institute evaluates organizations through their participation in and outcomes of the HR Best Practices Survey. This comprehensive survey encompasses six domains and addresses 20 topics from Career Development to Leadership and from Employee Wellbeing to Equity & Inclusion and Wellbeing, amongst others. The program has certified and recognized over 2,300 Top Employers in 121 countries/regions across five continents.  "Hovione is a company committed to excellence and differentiation and being a Top Employer is an integral component of Hovione's People Strategy. I am pleased to see that our continuous improvement program, supported by Top Employer´s best practices benchmarks, resulted in our progressing along multiple dimensions at all our locations”, commented Ilda Ventura, Vice-President for Human Resources and Member of the Management Board of Hovione.     Macau Special Administrative Region Douglas Lau, Human Resources Director for Hovione Macau, said that “It is a real achievement to be the first company in Macau to be a Top Employer. This demonstrates that companies in Macau can offer the same high quality workplace environment as anywhere else in the world. Coming so soon after Hovione was awarded the Medal of Merit from the Macau Government, it is also a further demonstration of how Hovione creates jobs that have real value to both our team members and the wider society. Portugal Catarina Tendeiro, HR Senior Director for Hovione Portugal, said that “We are thrilled to announce that Hovione has once again been recognized as Top Employer. This is a confirmation of our ongoing commitment to developing an exceptional workplace environment for our team members, who represent our most significant resource and our company´s main differentiator. I was especially pleased that this year’s report demonstrated improvement in several key areas, including Business and People Strategy, Leadership, Performance and Career and Learning. This demonstrates our desire to listen to feedback and to continue to improve our workplace experience.  USA Erin Tetreault, HR Director for Hovione New Jersey said, “We are thrilled to announce that Hovione has once again been certified as a Top Employer. We believe that our people are our strongest asset and this certification demonstrates our ongoing commitment to create a workplace culture that goes beyond safety and quality and helps all team members to feel truly valued. I was especially pleased that this years’ report showed improvement in several key areas, including Leadership, Work Environment and Employee Wellbeing. This demonstrates our desire to listen to feedback and to continue to improve our workplace experience." Ireland Imelda Cummins, HR Director for Hovione Ireland commented, “We are delighted that Hovione has once again been certified as a Top Employer. Hovione´s team members represent our strongest asset and enable us to offer our customers the high-quality products and services that Hovione is known for. It also shows our ongoing commitment to developing a great workplace environment. I was especially pleased that this year’s report demonstrated improvement in several key areas, including Diversity, Equity & Inclusion, Learning, Sustainability and Career Development. This demonstrates our desire to listen to feedback and to continue to improve our workplace experience.   About Hovione: Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About Top Employers Institute: Top Employers Institute is the global authority on recognising excellence in People Practices. We help accelerate these practices to enrich the world of work. Through the Top Employers Institute Certification Programme, participating companies can be validated, certified, and recognised as an employer of choice. In 2024, Top Employers Institute has certified more than 2300 organisations in 121 countries/regions. These certified Top Employers positively impact the lives of over 12 million employees globally.    

Press Release

Hovione certified as a Top Employer in all of its manufacturing sites

Jan 18, 2024

Pharmaceuticals manufacturer Hovione has been awarded a Medal of Merit for industry and commerce in the government’s 2023 honours list, with Chief Executive Ho Iat Seng praising the company’s contributions to Macao’s emerging life sciences industry. The Portuguese company’s Macao site manager, Eddy Leong, said in a statement that it was a “great honour” to receive the Medal of Merit – which he saw as a tribute to almost 40 years of local work in the science sector. “At Hovione, we like to say that we are ‘in this for life’ and I feel that this award reflects not only our long and successful history in Macao, but also points to our successful future here,” he said.  “It also reflects our commitment to work with partner organisations to create rewarding career opportunities in life sciences,” Leong added. Hovione was founded in 1959 in Portugal and opened its Macao plant in the mid-1980s. The facility produces generic active pharmaceutical ingredients and is located in Taipa, on the site of the old Him Un Iec Kei Chan firecracker factory. Other 2023 honourees include wushu athlete and Asian Games gold medalist Li Yi, who received a Silver Lotus, and the Portuguese-language educator Felizbina Carmelita Gomes – currently director of the D. José da Costa Nunes Kindergarten. Gomes was awarded a Medal of Merit for education.   Read more at Macao News  

Press Clipping

Hovione ‘delighted’ by its Medal of Merit

Dec 27, 2023

22 December, 2023, Hovione is delighted to announce that the Hovione Macau site has been awarded the Medal for Industrial and Commercial Merit by the Government of Macau, a Special Administrative Region of the People´s Republic of China. The site underwent its first of many successful FDA inspections in 1987 and ever since has produced off-patent pharmaceutical actives, which are sold in the global market and boost Macau´s exports. With 180 employees, it is the largest pharmaceutical site in Macau. Over the years, Hovione has worked with a range of governmental departments to support the development of the pharmaceutical industry in Macau. This includes collaborating with the Macau Labor Affairs Bureau to develop the local workforce and create careers in the pharmaceutical industry. Hovione also works with the Education and Youth Development Bureau to organize visits from schools and universities and to arrange internships within the company for students. Team members are also invited by Macau University to give lectures on good manufacturing practice (GMP) and chemical analysis. Eddy Leong, Site Manager of Hovione Macau said: “It is our great honor to receive this Medal of Merit. We would like to express our gratitude to the Macau SAR Government and all sectors of society for recognizing the company's nearly 40 years of presence and industrial activity in Macau. At Hovione, our motto is “In it for life” and this award not only reflects our long and successful history in Macau, but also points to our successful future here. It also reflects our commitment to work with partner organizations to create rewarding career opportunities in life sciences.” The Medals of Merit cover seven categories (Industrial and Commercial, Tourism, Education, Culture, Altruism and Sports). They are intended to reward individuals or organizations that stand out in the exercise of their professional activity.   About Hovione: Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices.  Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

Press Release

Hovione awarded prestigious industry medal by Macau Government

Dec 22, 2023

Hovione and Industrial Design Consultancy (IDC) have entered into a joint development of an innovative nasal powder delivery device technology supporting local, systemic, and nose-to-brain drug delivery. Nasal delivery is a simple and safe alternative to conventional delivery routes for drug delivery, which offers a faster onset of action. It is also seen as a promising pathway to deliver new drugs to the brain and treat diseases of the central nervous system. Lisbon, November 29, 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action. Additionally, it is emerging as a promising pathway to deliver new drugs to the brain to treat diseases of the central nervous system (CNS).  Hovione and IDC have been working together to accelerate the development and commercialization of two new active nasal powder delivery devices, one single-use and one multidose. The devices enable broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. By using standard capsules and filling equipment, they also have the potential to simplify drug product development and manufacturing.  "Intranasal drug delivery is gaining momentum across a number of applications, including mucosal vaccination and CNS treatments bypassing the blood-brain barrier", says Dr. Jean-Luc Herbeaux, Hovione's CEO. He adds: "Our partnership with IDC, a company with vast experience in industrial design, mechanical and electronic engineering of medical devices, enables Hovione to offer a complete solution for nasal powder delivery – covering Active Pharma Ingredients (APIs), formulation, filling, analytics and device design and manufacturing - that address the needs of pharmaceutical companies and patients".  “By combining Hovione’s capabilities in pharmaceutical development, formulation and manufacturing with IDC’s device development expertise, this partnership offers customers a nasal powder delivery solution which can be rapidly adapted to new pharma compounds and therapies” explains IDC´s Managing Director, Dr Stephen Knowles, “Our joint development team has done incredible work to create unique, high performance nasal powder delivery devices.” Hovione will offer the new devices on an exclusive basis as part of its integrated offer for nasal drug development and manufacturing.    About Hovione: Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices.  Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About IDC: IDC is a leading medical product design and development consultancy dedicated to using its creativity, insight, experience and expertise to make the best possible products and deliver commercially successful products for clients and partners.  With over 50 years’ experience and ISO13485 compliant processes and facilities in London and Shanghai, IDC’s experts in user research, design, mechanical and electronics engineering and rapid prototyping work to create award-winning, world-leading products for global markets.    IDC’s track record includes many commercialized drug delivery devices across inhalation, nasal and injectables with a focus not just on design but also ensuring a smooth transition to production and regulatory approvals. IDC’s mission statement is “We innovate to create successful products which improve people’s lives”.  

Press Release

Hovione expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC

Nov 29, 2023

Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremophiles. The acquisition provides Hovione with new high-performance functional materials, which have shown potential in stabilizing biopharmaceuticals. Lisbon, November 16, 2023, Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, today announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on the synthesis, development, and commercialization of bio-inspired synthetic sugars, targeting enhanced stabilization, reduced viscosity and delivery performance of proteins and other biopharmaceuticals.  ExtremoChem developed a library of proprietary sugars, synthetic analogues of natural molecules found in extremophiles – organisms capable of withstanding the most uninhabitable environments. These sugars have shown potential in overcoming challenges associated with the stabilization of biopharmaceuticals during production, purification, formulation, and transportation. Dr. Jean-Luc Herbeaux, Hovione’s CEO commented: "Proteins and other biopharmaceuticals account for a significant share of our customers ´pipelines.  The acquisition of ExtremoChem’s synthetic sugars combined with Hovione's particle engineering capabilities provides our customers with a unique set of tools to optimize formulations that address stability issues encountered during the life cycle of biopharmaceuticals.” Filipe Aguiar, ExtremoChem’s Managing Director commented: “I am delighted that ExtremoChem has been acquired by Hovione. Hovione has a long history of developing and industrializing innovative technologies for the pharma industry. This acquisition will help ensure that the science we developed at ExtremoChem will have a wider and faster market adoption.” The announcement of this acquisition demonstrates Hovione´s commitment to expand its technology platforms. The company is investing both in new assets and innovative technologies to meet customer demand for integrated and differentiated development and manufacturing services in drug substance, particle engineering and drug product.   About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices.  Hovione's culture is based on innovation, quality, and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About ExtremoChem ExtremoChem is a chemical synthesis start-up company focused on the development of organic synthetic sugars for the stabilization of biologicals under stress conditions.     

Press Release

Hovione acquires ExtremoChem and its portfolio of proprietary sugars to support customers with stabilization and delivery of biopharmaceuticals

Nov 16, 2023

In the year 2021, when COP26 was held in Glasgow, Sterling Pharma Solutions came out announcing an ambitious target: to reduce the CDMO’s overall emissions by 50% by 2025 and by doing so, joining the international community’s fight against climate change. The CDMO Recipharm expanded its pressurized metered dose inhalers (pMDI) product development the following year to accommodate the switch to new propellants, which have 90% to 99.9% lower global warming potential than HFA134a. In the same year, WuXi STA won top scores from EcoVadis, a provider of business sustainability ratings, for their API and formulations factories located in China. Again, in January, Samsung Biologics was awarded the 2022 Sustainable Markets Initiative’s Terra Carta Seal in recognition of its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier. Similarly, Cytiva says its goal is to eliminate polystyrene from the company’s packaging materials and supply chain by 2025. These are just a few examples of a growing trend. A number of CDMOs are accelerating their environmental drive setting themselves far more ambitious targets than these as sustainability goals are now becoming one of the most urgent business strategies facing pharma companies. Presently, analysts say that there is a move away from sustainability being seen as something that is nice to have, to something more fundamentally important to businesses. "Sustainability commitments are no longer just desirable," says Jon Peers, director of sustainability at Hovione. "They are becoming mandatory, both directly by our regulatory authorities and indirectly by the regulatory and financial requirements faced by our customers." Hovione, a leader in spray drying and particle engineering, became a Certified B Corp in 2017 integrating an innovative community of companies that use the power of business to solve social and environmental problems. Pharma’s outsized impact Medicine making leaves an environmental impact which is quite massive. Estimates show that the pharmaceutical sector is accountable for as much as 4.4% of worldwide emissions—and if no action is taken—its carbon dioxide, a greenhouse gas (GHG), emissions are predicted to triple by 2050. Not only manufacturing but the distributing and transporting of medicines from the factory to the patient also carries a substantial environmental footprint. According to the Sustainable Markets Initiative’s (SMI) “Decarbonizing Healthcare Supply Chains” whitepaper, the biopharma industry is responsible for 4–5% of global GHG emissions, with most of its carbon footprint coming from supply chain, manufacturing, retail, and logistics. Having felt the heat, many leading pharma companies are already ahead of the curve on the path to net-zero carbon emissions. They have made carbon neutrality and net-zero pledges, some for as early as the next decade. Sustainability metrics: High on the agenda CDMOs demonstrate a strong determination to reduce their carbon emissions as environmental performance is being added to the list of demands by their clientele. Industry reports show that full waste recycling, green power percentage and green chemistries currently play a crucial role during negotiations between pharmaceutical companies and the CDMOs. These “sustainability metrics” are becoming increasingly important even as technology, track record, capacity, and cost are still the most important criteria for selecting CMOs/CDMOs. "Recognizing our commitment and progress made towards our sustainability targets, clients will seek out not only providers of CDMO services but also those companies with the competence to execute these services in harmony with the client’s respective sustainability goals," says Paul Zuechner, director, sustainability and reliability engineering, pharma services, Thermo Fisher Scientific. Thermo Fisher, which offers end-to-end solutions to small molecules as well as biologics, announced an acceleration of the target to reduce scope 1 and 2 GHG emissions to more than 50% by 2030. Zuechner maintains that the increasing focus on sustainability, resource and decarbonization quantifications is now elevating sustainability towards an equal project deliverable on par with cost, quality, and timelines. The sustainability initiatives by CDMOs are not only driven by customer preference but also by regulatory requirements, according to Peers of Hovione. Regulated and standardized reporting is there. The European Corporate Sustainability Reporting Directive (CSRD) together with the European Sustainability Reporting Standards (ESRS) is significantly raising the required levels of compliance. On top of this, businesses must meet their stakeholder’s requirements to provide material information that stands up to scrutiny. Headquartered in Loures-Portugal, Hovione believes that it is simply not possible to meet the challenging goals that have been set by the companies themselves on sustainability without further innovation, particularly through process intensification and the greening of pharmaceutical intermediate and API manufacturing. Safety via process efficiency Without question, manufacturers are aggressively pursuing various strategies to enhance processes as it becomes a business imperative for the service providers. "Olon tries to optimize plants' performances, in order to reduce the amount of energy, materials and natural resources they need,'' says Giorgio Bertolini, senior vice president of R&D, Olon Group, a global leader in the development and production of APIs, headquartered in Milan, Italy. Olon is working on cutting-edge R&D processes applied both to chemistry, in terms of flow chemistry, photochemistry, and electrochemistry, and to biotechnologies. Investing in and developing technological advances allows the organization to combine well-established practices with new ones, to guarantee efficient and successful manufacturing processes, at the same time ensuring safe, fast and cost-effective commercial processes. "We consider climate protection and the related reduction of GHG emissions to be a top priority," emphasizes Bertolini. To increase efficiency and reduce the energy required for production, especially in the functioning of reactors, Olon is implementing several continuous manufacturing processes, investigating both the flow chemistry approach and the continuous stirred tank reactors (CSTR) These approaches entail leaving no batch reactors with loading and unloading phases but keeping constantly active production units—either microreactors or small classical reactors. The outcome is that, at the same levels of production, continuous manufacturing processes can reduce the footprint of the manufacturing process in comparison with standard methods. This innovative production technique, he explains, enables a double positive impact in terms of sustainability. Indeed, it allows for the use of smaller amounts of material for the unit time, therefore resulting in increased local temperature control and in the possibility to avoid extreme temperatures, making the manufacturing process less energy intensive. It also provides greater safety for operators. The industry is now facing a change of paradigm, avers Bertolini, in which there is a continuous exchange of knowledge and information between the chemical and engineering sectors, which eventually results in the creation of new specific know-how and business synergies. Olon started constructing a new facility at its Rodano site (Milan, Italy) dedicated to ultra-potent compounds, used for antibody-drug conjugates (ADCs). Circular business models that combine a responsible use of natural resources and raw materials with a responsible waste management approach are what Olon strives to promote, according to Bertolini. Greening the supply chain To reduce effluents and design safer alternatives to hazardous processes organizations extensively explore the use of safer and more sustainable chemicals. This green chemistry approach can minimize the risk of impact on the environment to a great extent. Olon, for instance, is focusing on green chemistry projects for the replacement of chlorinated solvents and the reduction of critical substances which could be particularly toxic, especially in new manufacturing processes. Not only in manufacturing, quite a few companies are investing in greener biofuels (rather than diesel) for vehicles. As mentioned, distributing and transporting medicines from the factory to the patient also leaves a large carbon footprint. Temperature-sensitive products are loaded onto refrigerated vehicles to maintain cold-chain which require a considerable amount of energy to power. Environmental credentials are now integral to all supply chain decisions. There is almost a universal consensus on this approach, shows the CPHI sustainability sentiment index. In data released ahead of CPHI Frankfurt 2022, 95% of industry executives suggest it is either “important” or “extremely important” (52%) to have visibility on supply chain partners. Scope 3 emissions: Key challenge In comparison to the scope 3 tally that falls not within the organization's boundary, scopes 1 and 2 emissions are relatively minor. However, within these scopes, electrical energy consumption in manufacturing and the fugitive emissions from hydrofluorocarbons (HFC) released during pMDIs product lab testing are the highest. pMDIs and anesthetic gases can be particularly serious for global warming. The UK and several countries in the EU block including Belgium, and the Netherlands are now promoting dry powder inhalers in prescription guidelines. Meanwhile, the common general anesthetic desflurane is being replaced by lower-carbon alternatives in countries like Sweden. Scope 3 emissions, however, make up the majority of the pharma sector’s carbon footprint. Even though many CDMOs have set ambitious targets like striving for carbon neutrality across the entire value chain already by 2030, many are still simply focusing on scope 1 and 2 emissions. Observers say that this is largely because the need for sustainability in the pharmaceutical industry has become more apparent only in recent years. Another concern is the cost factor. According to Peers of Hovione, decarbonization costs in particular can be very expensive and require strategic planning and commitment from senior management to meet associated capital and operational costs. The sustainability challenge, he says, needs to be considered throughout the drug development life cycle, starting from simple assessments against sustainability principles and metrics early on and growing in detail and robustness as the drug progresses through the cycle. Shift in focus Experts, however, see a shift across the industry. Discussions about sustainability are taking place at the highest levels. An increasing number of pharmaceutical companies are prioritizing it when discussing projects with their CDMO partners. "Be it the fulfillment of new technical capabilities, increased production capacities, advancing regulatory compliance and now sustainability target introductions—it’s natural for us to solve for and achieve our customers’ product development, manufacturing, and corporate goals in partnership,” says Zuechner of Waltham, Massachusetts-headquartered Thermo Fisher. It will be essential for drug makers and their CDMO partners to work together on questions of sustainability, and to be ready with a sustainability agenda before starting to work on the project, in the coming years. It is important for CDMOs, says Peers, that their clients and suppliers share the same vision of a more sustainable industry as collaboration across the value chain is key to leveraging knowledge and driving change.   Read the article at contractpharma.com  

Press Clipping

Net-Zero Pledge: CDMOs Go Greener

Jul 19, 2023

Responsible for 39% of the nation’s total annual exports, the Irish pharmaceutical sector continues to expand its capabilities   Ireland’s life sciences sector is internationally renowned for its operational and innovational excellence, with 19 out of the top-20 global pharmaceutical and biopharmaceutical giants having a presence in the country. Overall, more than 85 pharmaceutical companies are currently operating in Ireland and the sector employs over 42,500 people. And this talent base is constantly expanding, thanks to continuous new investment into the sector. “We are the world’s third-largest exporter of pharmaceuticals and we have a good reputation for strong regulatory compliance and quality. Our regulators are seen around the world as some of the leading lights in setting standards. As a result, pharmaceutical companies in Ireland go beyond compliance, which gives them a competitive advantage,” says Paul Downing, general manager of Hovione, the leading international contract development and manufacturing organization (CDMO) that specializes in fully integrated innovative services for drug products, product intermediates and substances.    PAUL DOWNING GENERAL MANAGER, HOVIONE “Pharmaceutical companies in Ireland go beyond compliance, which gives them a competitive advantage.”   With state-of-the-art manufacturing facilities in Ireland, the US, Portugal and China — all of which have high regulatory compliance — Hovione has a global employee base of nearly 2,500 people and in its 63-year history has had more than 41 regulatory inspections from authorities such as the US Food and Drug Administration with no product recalls and no warning letters being issued. Something that Downing is exceptionally proud of. “We’re an expert organization with capabilities in technology transfer and new product introductions and, from a CDMO perspective, we’re recognized as a world leader in spray drying,” he says. “We’re also a progressive company and we go above and beyond compliance; we always want to learn and give our customers more, because customer satisfaction is at the heart of everything we do.” Hovione began its operations in Cork in 2009. Since then, it has quadrupled its Irish assets, client base, sales and employees, which has given it the right ecosystem to take on large customer projects. As with any industry, the digital revolution is changing all facets of the pharmaceutical business and Hovione itself has implemented a host of new digital tools at its Irish facilities in recent years. “One example of this is an electronic laboratory notebook, which is a digitalization of our core activities in research and development and our quality control laboratories. That has driven efficiency and standardization,” says Downing. “As a company, we have other global initiatives, including a plant data management system, which is a central hub for all our data on trends and information that allows us to analyze and share that data. “In addition, we’ve started to adopt a manufacturing execution system and are automating electronic batch records. That’s the journey we’re on. Here in Ireland, there are lots of advocates for industry 5.0. We’re watching that brief to see how it evolves and whether we can tap into that as well.”   Future growth of the biopharma industry Ireland’s pharmceutical sector began to become an international presence in the 1960s after the arrival of pharma giant Pfizer, which was followed by names like Merck, MSD, SmithKline, GSK, Eli Lilly, Bristol Myers Squibb, Alexion and Regeneron — and by 2021, the sector was generating over $85 billion a year from its exports. Investments continue to flood in to the tune of around $1-$2 billion annually, and this could soon increase, as the association that represents Ireland’s biopharma and chemical industry, BioPharmaChem Ireland —part of the wider trade body Ibec — has recently launched a five-year strategy to further develop the sector.    "We’re prioritizing skills and talent,” outlines Matt Moran, director of BioPharmaChem Ireland. “For example, we have established an apprenticeship program, which we work on with the government, that is non-traditional and vocational. In the past, companies would normally have employed university graduates, but now there is an opportunity for school leavers to work in the industry and acquire qualifications at the same time. We also operate an industry-led Skillnet training initiative, through which we arrange for training programs to be delivered to the industry to fill skill gaps. The association is also prioritizing the continued growth and competitiveness of all the sub sectors of the industry, including active pharmaceutical ingredients, biotech and finished products, states Moran, who adds: “Some of the newer areas we’re exploring at the moment are pharma 5.0, which involves empowering employees as well as deploying technology, sustainability in manufacturing, cell and gene therapies and very advanced therapeutics. We also want to grow our indigenous base of startups and to expand our footprint to include additional aspects of the industry, such as global business services, clinical research and more engagement research. That’s the future.”   Read the full article at BusinessFocus.org    

Article

Excellence in pharmaceuticals

Jun 30, 2023

This year’s theme for International Women in Engineering Day is #makesafetyseen to celebrate the achievements of women around the world in engineering. Hear from some of our engineers as they share their career journeys and empower others to break barriers in the healthcare field. Thank you to Ana Rafael (Principal HSE Specialist) Catarina Coelho (Senior QC Technical Specialist), and Luísa Paulo (Corporate Quality Senior Director I) for making safety seen.  Read their statements here.   “I would like to say a word to empower young girls and show them the incredible potential of women in engineering. Engineering is not just about math and science — it's about designing safer, environmentally friendly systems, collaborating, and embracing entrepreneurship. As women in engineering, we are making a profound impact on society. I proudly graduated in Chemical Engineering from the University of Coimbra, where both boys and girls were determined to leave their mark on the world. I began my career as a researcher, simulating distillation processes. However, my passion for the environment led me to shift my focus towards engineering design for biofuels and environmental treatment plants. It was then that everything fell into place — I knew I wanted to create a better world. Years later, I seized the opportunity to start my own business, dedicated to enhancing the environmental efficiency and sustainability of various industries across Europe, KSA, and Angola. This journey taught me the importance of sustainable practices and the dedication required to secure our place in the future. Today, at Hovione, I’m able to balance both of my passions: contributing to life-saving medicines and ensuring that all of us do our jobs in a safely manner. For ourselves and for the communities where we are in. For the past 8 years, I have led and managed teams and projects, guiding Hovione sites towards a better, safer and more sustainable future. I never stop learning and embracing challenges. I believe in the power of women, driving positive change and breaking barriers. Together, we can create a safer world where women in engineering thrive and shape a brighter future for all." Ana Rafael - Principal HSE Specialist Hovione Portugal    "On International Women in Engineering Day, I take this time to reflect on my journey as a woman in the engineering field. One of the most rewarding experiences in my journey was the opportunity to work as Senior Analytical Chemist at Hovione. In this role, I had the privilege of contributing to the design and implementation of innovative solutions. On this special day, let us celebrate the remarkable achievements of women engineers worldwide. Together, we are transforming the landscape of engineering, breaking down barriers and forging a path for future generations of aspiring engineers." Catarina Coelho - Senior QC Technical Specialist Hovione Portugal   "I have been working as a Chemical Engineer for 40 years and I would like to motivate the young women who love engineering to pursue their dream. At Hovione, I have always felt appreciated and encouraged by my colleagues." Luísa Paulo - Corporate Quality Senior Director I Hovione New Jersey

News

2023 International Women Engineering Day

Jun 23, 2023

Lisbon, May 3, 2023 - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to develop the Sunriser© Dry Powder Inhaler. This innovative and best-in-class capsule-based platform is flexible enough to address both the challenges of classic carrier-based and spray-dried engineered formulations. This partnership is an extension of a successful collaboration that has spanned several years on developing and commercializing innovative dry powder inhalation devices. As part of the joint development agreement, Hovione will exclusively partner with Presspart to exploit the Sunriser© device in the field of engineered formulations for dry powder inhalation. Presspart will remain responsible for the manufacturing of the Sunriser© device. To provide further insights into the benefits of this partnership for the industry, a joint workshop will be held today, May 3rd, at the Respiratory Drug Delivery (RDD) Europe 2023. "New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,” says Dr. Jean-Luc Herbeaux, Hovione´s CEO. He adds: “We are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”  Christian Kraetzig, President of H&T Presspart, commented “Following our successful collaboration with Hovione on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with Hovione in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology.” Pharmaceutical companies partnering with Hovione to develop their new inhalable drugs using the Sunriser© device can leverage Hovione´s unparalleled expertise in inhalable APIs, formulation, filling, and analytical characterization. Additionally, with H&T Presspart's state-of-the-art device manufacturing and supply, from lab to commercial cGMP scale, companies can benefit from a comprehensive approach to drug development. This partnership enables pharmaceutical companies to access top-notch expertise and cutting-edge technology, ensuring the successful development and commercialization of innovative inhalable drugs.   About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices.  Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About H&T Presspart H&T Presspart is a market leading manufacturer of drug delivery devices and components with more than 50 years' experience and enjoys a worldwide reputation for competence, quality and innovation in the pharmaceutical market. With more than 30 engineers and scientists, H&T Presspart supports its customers in bringing to market new drug delivery devices. H&T Presspart has 4 European manufacturing sites in Germany, Spain, Switzerland and the UK and also has sales representation in China, India, the U.S.A. and Uruguay.     

Press Release

Hovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery

May 03, 2023

  The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased Hovione and H&T Presspart have entered into a strategic partnership to advance the development of Presspart's Sunriser Capsule-based Dry Powder Inhaler platform.  The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to develop the Sunriser Dry Powder Inhaler. This innovative and best-in-class capsule-based platform is flexible enough to address both the challenges of classic carrier-based and spray-dried engineered formulations. This partnership is an extension of a successful collaboration that has spanned several years on developing and commercialising innovative dry powder inhalation devices. As part of the joint development agreement, Hovione will exclusively partner with Presspart to exploit the Sunriser device in the field of engineered formulations for dry powder inhalation.  Presspart will remain responsible for the manufacturing of the Sunriser device. To provide further insights into the benefits of this partnership for the industry, a joint workshop will be held on May 3, at the Respiratory Drug Delivery (RDD) Europe 2023. "New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,” said Dr Jean-Luc Herbeaux, Hovione’s CEO. He added: “We are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”  Christian Kraetzig, President of H&T Presspart, commented: “Following our successful collaboration with Hovione on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with Hovione in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology.” Pharmaceutical companies partnering with Hovione to develop their new inhalable drugs using the Sunriser device can leverage Hovione´s unparalleled expertise in inhalable APIs, formulation, filling, and analytical characterisation.  Additionally, with H&T Presspart's state-of-the-art device manufacturing and supply, from lab to commercial cGMP scale, companies can benefit from a comprehensive approach to drug development. This partnership enables pharmaceutical companies to access top-notch expertise and cutting-edge technology, ensuring the successful development and commercialisation of innovative inhalable drugs.    Read the article at manufacturingchemist.com  

Press Clipping

Hovione and Presspart extend technology partnership

May 03, 2023

Contact Us

If you would like to learn more about Hovione, kindly fill in the form below and we will be revert to you soon.